Healthcare >> CEO Interviews >> October 19, 2009
Dr. Jonathan Lewis, M.D., Ph.D., is Chief Executive Officer and a Director of ZIOPHARM Oncology, Inc., having served in these capacities since January 2004. Additionally, Dr. Lewis has been Chief Medical Officer since June 2008. From July 1994 until June 2001, Dr. Lewis served as professor of surgery and medicine at Memorial Sloan-Kettering Cancer Center. He has been actively involved in leading translational and clinical research in cancer and is globally recognized by patient advocacy groups. He has received numerous honors and awards in medicine and science, including the ASCO Young Investigator Award, the Kristen Carr Fellowship, the Yale University Ohse Award, the Royal College of Surgeons Trubshaw Medal, and the Sarcoma Foundation of America Hope and Vision Award. He served as Chief Medical Officer and Chairman of the Medical Board at Antigenics, Inc., from June 2000 to November 2003. He also serves as a Director on the board of the Police Organization Providing Peer Assistance of the New York Police Department. Dr. Lewis serves on the Medical Advisory Board of the Sarcoma Foundation of America and on the Scientific Advisory Council of the Hope Funds for Cancer Research. Profile
TWST: Let's start with a history of ZIOPHARM.
Dr. Lewis: The derivation of the "Z" ZIOPHARM (ZIOP)comes from Z in Ancient Greek, a symbol that means "in pursuit of the truth,"
